ASYMCHEM LAB.(TIAN.)H YC1
Research ASYMCHEM LAB.(TIAN.)H YC1 (7K90) on Bullrun: market cap EUR 4.44B, P/E 30.8, dividend yield 1.2%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker7K90
- ExchangeF
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 4.44B
- P/E30.8
- Dividend yield1.2%
- Financial periodQ1 2026
- RevenueCNY 1.80B
- Net incomeCNY 304.32M
- Free cash flowCNY 179.11M
- Gross margin43.0%
Valuation Snapshot
latest market cap is EUR 4.44B; P/E is 30.8; dividend yield is 1.2%.
Peer valuation comparison
Latest P/E is 30.75x versus a Healthcare sector median of 24.46x (25.7% above).
Latest dividend yield is 1.22% versus a Healthcare sector median of 2.11% (42.2% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-14 | EUR 4.44B | 30.8 | 1.2% | 0.17 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.17 EUR, yield 1.2%.
About ASYMCHEM LAB.(TIAN.)H YC1
Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization (CDMO) solutions in Mainland China and internationally. It is involved in small molecule CDMO services for projects covering multiple major disease treatment areas, such as oncology, antiviral, anti-infective, cardiovascular, and diabetes; chemical macromolecule CDMO; biomacromolecule CDMO, including antibody-peptide conjugates; formulation CDMO; clinical CRO; synthetic biology and new technology output business.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ASYMCHEM LAB.(TIAN.)H YC1's market cap?
ASYMCHEM LAB.(TIAN.)H YC1's market capitalization is EUR 4.44B.
What is ASYMCHEM LAB.(TIAN.)H YC1's P/E ratio?
ASYMCHEM LAB.(TIAN.)H YC1's price-to-earnings (P/E) ratio is 30.8.
Does ASYMCHEM LAB.(TIAN.)H YC1 pay a dividend?
ASYMCHEM LAB.(TIAN.)H YC1 has a dividend yield of 1.2%.
What does ASYMCHEM LAB.(TIAN.)H YC1 do?
Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization (CDMO) solutions in Mainland China and internationally. It is involved in small molecule CDMO services for projects covering multiple major disease treatment areas, such as oncology, antiviral, anti-infective, cardiovascular, and diabetes; chemical macromolecule CDMO; biomacromolecule CDMO, including antibody-peptide conjugates; formulation CDMO; clinical CRO; synthetic biology and new technology output business.